Effects of eicosapentaenoic acid on left ventricular function in patients with non-ischaemic cardiomyopathy

Trial Profile

Effects of eicosapentaenoic acid on left ventricular function in patients with non-ischaemic cardiomyopathy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Ethyl eicosapentaenoic acid (Primary)
  • Indications Chronic heart failure
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 01 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top